SAN FRANCISCO, CA--(Marketwired - December 17, 2013) - Kindred Biosciences, Inc. (NASDAQ: KIN) (Kindred Bio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the closing of its initial public offering of 8,625,000 shares of its common stock at an initial public offering price of $7.00 per share, which included 1,125,000 shares sold pursuant to the exercise in full by the underwriters of their over-allotment option. Kindred Bio's common stock is listed on The NASDAQ Capital Market under the trading symbol "KIN." Kindred Bio estimates net proceeds from the offering to be approximately $56,148,750 million, after deducting underwriting discounts and commissions and estimated offering expenses.
BMO Capital Markets and Guggenheim Securities acted as book-running managers for the offering. Roth Capital Partners acted as co-manager for the offering.
The offering is being made only by means of a prospectus forming part of an effective registration statement. Copies of the prospectus relating to the offering, when available, may be obtained from BMO Capital Markets Corp. at 3 Times Square, 27th Floor, New York, NY 10036, Attention Equity Syndicate Department, by telephone at (800) 414-3627 or by email to firstname.lastname@example.org and from Guggenheim Securities, LLC at 330 Madison, 8th Floor, New York, NY 10017, Attention Equity Syndicate Department, by telephone at (212) 518-9349 or by email to GSEquityProspectusDelivery@guggenheimpartners.com.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.
About Kindred Biosciences
Kindred Biosciences is a development stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company's lead product candidates are CereKin for the treatment of osteoarthritis pain and inflammation in dogs, AtoKin for the treatment of atopic dermatitis in dogs, and SentiKin for the treatment of post-operative pain in dogs.